Achilles Therapeutics Competitors

Immunocore (NASDAQ:IMCR) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Immunocore and Achilles Therapeutics, as provided by MarketBeat.com.

Immunocore presently has a consensus target price of $54.3333, indicating a potential upside of 32.84%. Achilles Therapeutics has a consensus target price of $21.20, indicating a potential upside of 62.95%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Immunocore.

Profitability

This table compares Immunocore and Achilles Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Immunocore and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Achilles Therapeutics beats Immunocore on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Seer and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Seer and Achilles Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and Achilles Therapeutics, as provided by MarketBeat.

Seer currently has a consensus target price of $66.3333, suggesting a potential upside of 130.72%. Achilles Therapeutics has a consensus target price of $21.20, suggesting a potential upside of 62.95%. Given Seer's higher possible upside, analysts clearly believe Seer is more favorable than Achilles Therapeutics.

Summary

Achilles Therapeutics beats Seer on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares ImmunityBio and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ImmunityBio and Achilles Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ImmunityBio and Achilles Therapeutics, as provided by MarketBeat.

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 64.58%. Achilles Therapeutics has a consensus target price of $21.20, suggesting a potential upside of 62.95%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Achilles Therapeutics.

Summary

ImmunityBio beats Achilles Therapeutics on 2 of the 3 factors compared between the two stocks.

Achilles Therapeutics (NASDAQ:ACHL) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Achilles Therapeutics and BioAtla's top-line revenue, earnings per share and valuation.

Profitability

This table compares Achilles Therapeutics and BioAtla's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Achilles Therapeutics and BioAtla, as reported by MarketBeat.com.

Achilles Therapeutics currently has a consensus price target of $21.20, suggesting a potential upside of 62.95%. BioAtla has a consensus price target of $62.75, suggesting a potential upside of 30.73%. Given Achilles Therapeutics' higher possible upside, equities research analysts plainly believe Achilles Therapeutics is more favorable than BioAtla.

Cullinan Oncology (NASDAQ:CGEM) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cullinan Oncology and Achilles Therapeutics, as reported by MarketBeat.

Cullinan Oncology presently has a consensus price target of $48.75, suggesting a potential upside of 60.10%. Achilles Therapeutics has a consensus price target of $21.20, suggesting a potential upside of 62.95%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Cullinan Oncology.

Valuation & Earnings

This table compares Cullinan Oncology and Achilles Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Cullinan Oncology and Achilles Therapeutics' net margins, return on equity and return on assets.

Edgewise Therapeutics (NASDAQ:EWTX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Edgewise Therapeutics and Achilles Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Edgewise Therapeutics and Achilles Therapeutics, as reported by MarketBeat.

Edgewise Therapeutics presently has a consensus price target of $34.25, suggesting a potential upside of 30.13%. Achilles Therapeutics has a consensus price target of $21.20, suggesting a potential upside of 62.95%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Edgewise Therapeutics.

Valuation & Earnings

This table compares Edgewise Therapeutics and Achilles Therapeutics' top-line revenue, earnings per share and valuation.

Summary

Achilles Therapeutics beats Edgewise Therapeutics on 2 of the 3 factors compared between the two stocks.